Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.
-
Upload
teagan-bellock -
Category
Documents
-
view
226 -
download
5
Transcript of Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.
![Page 1: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/1.jpg)
Lead
Sources of Occupational Exposure, Clinical Toxicology, and Control
![Page 2: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/2.jpg)
Lead in the Environment
• Lead (207Pb) is a natural element, heavy metal, end product of radionuclide decay
• Radioactive lead (210Pb, t1/2 = 22 y) is a convenient way to trace lead
• Lead was insignificant environmentally until about 1800
• Human activity has mobilized lead in the environment
![Page 3: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/3.jpg)
Useful Properties of Lead
• Ductility
• Low melting point
• Density, absorption of radiation, sound and vibration
• Chemical properties (e.g. combines with nitrogen)
• Resists acid and corrosion
![Page 4: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/4.jpg)
Historical Sources of Lead Exposure
Ancient/Premodern History
• Lead oxide as a sweetening agent
• Lead pipes (“plumbing”)
• Ceramics• Smelting and foundries
Modern History• Gasoline• Ceramics• Crystal glass• Soldering
– pipes– “tin” cans– car radiators
• House paint
![Page 5: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/5.jpg)
Contemporary Sources of Lead Exposure
• Residue of leaded gasoline• Lead smelting and recycling• Solder (Pb + Sn), welding (minor)• Metalworking• Ammunition and explosives• Exterior paints and remediation• Avocational exposure in crafts• Kohl and certain herbal remedies
![Page 6: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/6.jpg)
Future Sources of Exposure to Lead
• Gasoline, in some developing countries• Plastics containing Pb additives (e.g. one type
of “thin” Venetian blinds)• Compounding “litharge”, used in making
ferrite ceramic magnets• Pb compounds with piezoelectric and
thermoelectric properties• Unregulated cosmetics, remedies
![Page 7: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/7.jpg)
Settings for Lead Exposure
• Smelting and metalworking
• Lead sulfate battery operations
• Activities related to firearms and ammunition
• Crafts involving glass, ceramics
• Hazardous waste disposal
• Imported or customized products
![Page 8: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/8.jpg)
Biologically Important Properties of Lead
• Readily combines with sulfide, sulfhydryls
• Affinity for bone and other calcified tissue
• Readily absorbed and mobilized in the body
• Cumulative body burden
• Narrow margin between population reference levels and toxicity levels
• OrganoPb compounds more bioavailable
![Page 9: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/9.jpg)
Lead Exposure in Children
• Pica and passive exposure: oral
• Pb removed from gasoline
• Blood Pb, FEP• CNS more likely to be
affected• Needleman
controversy
![Page 10: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/10.jpg)
Lead Exposure in Adults
• Mostly occupational: inhalation
• Maintenance at workplace
• Peripheral neuropathy more common
• Blood Pb, ZPP• Renal effects more
likely
![Page 11: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/11.jpg)
Cardinal Symptoms of Lead Intoxication
Acute• GI effects
– colic, severe pain– severe constipation
• Acute encephalopathy• Acute nephropathy
Children• Growth retardation• Behavioural
Chronic• Peripheral, central
neuropathy• Cardiac toxicity • Chronic nephropathy• Saturnine gout• Reproductive effects• Hypertension?• Anemia
![Page 12: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/12.jpg)
Signs of Extreme Lead Toxicity
• Acute lead encephalopathy– fatal in 25%– poor prognosis for full neurological recovery– severe clinical impairment in 40%
• Severe lead colic
• “Burtonian” lines (gingival deposition of Pb sulfide)
![Page 13: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/13.jpg)
Mechanisms of Damage to the Nervous System by Lead
Central• Cerebral edema• Necrosis of brain tissue• Glial proliferation around blood vessels
Peripheral• Demyelination• Reversible NCV• Irreversible axonal degeneration
![Page 14: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/14.jpg)
Neurological Manifestations of Lead Toxicity
Central/Pediatric• Lethargy, wakeful• Irritability• Clumsiness, ataxia• Projectile vomiting• Visual s• Delerium, convulsions,
coma IQ performance
Peripheral/Adult• Lead palsy
– median n.c. slowing
– wrist/foot drop
– demyleinating disease
• Lead colic• Muscle weakness• Behavioural, memory
![Page 15: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/15.jpg)
Anemia and Lead Toxicity
• Normochromichypochromic, normocyticmicrocytic
• Reduced rbc survival time• Compensatory rbc production
– reticulocytosis
• Basophilic stippling– variable– represents damaged cell organelles, RNA
![Page 16: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/16.jpg)
Haeme Synthesis and Lead Toxicity
• Pb inhibits -aminolevulinic acid dehydratase -ALA in urine
• Pb inhibits co-proporphyrinogen decarboxylase Co-proporphyrinogen in urine
• Pb inhibits ferrochelatase Protoporphyrine IX accumulates in rbcs
• FEP, ZPP tests are based on this
![Page 17: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/17.jpg)
Diagnostic Criteria for Lead Toxicity (CDC)
• Blood– Blood lead > 80 g/dL– FEP > 190 g/dL– ZPP
• Urinary Pb Excretion (24 hour)– Pb > 0.15 mg/L -ALA > 19 mg/L– Coproporphyrin III > 150 g/L
![Page 18: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/18.jpg)
Other Considerations in the Diagnosis of Lead Toxicity
• Blood lead is most generally useful• FEP not useful below about 20 g/dL• Evidence clearly suggests that children
should be considered at risk if BPb > 10 g/dL
• Early evidence that there may be risk at 5 g/dL
• Congenital anomalies have been reported
![Page 19: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/19.jpg)
Toxicokinetics of Lead, I
• Ingestion (children), inhalation (adults)
• Readily absorbed by inhalation route
• Slow absorption by ingestion, with Fe deficiency
• OrganoPb compounds (e.g. Et4Pb) much more rapidly absorbed
• Cumulative exposure
![Page 20: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/20.jpg)
Toxicokinetics of Lead, II
• Carried by red cell, mostly bound to haemaglobin A2
• Rapidly distributed perfusion
• Affinity for bone, which acts as sink (94%)
• Bone constitutes reservoir in equilibrium with blood; turnover slow
• t = 28 - 36 days in adult
![Page 21: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/21.jpg)
Toxicokinetics of Lead, III
• Inorganic Pb is not metabolised
• Organic (alkyl) Pb compounds are dealkylated in the liver
• Dealkylation involves cytochrome P450
• Some alkyl Pb is dealkylated, stays behind as inorganic Pb, and remobilizes
• Children have much less capacity to metabolize than adults
![Page 22: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/22.jpg)
Toxicokinetics of Lead, IV
• Excretion of Pb generally reflects body burden, not route of exposure
• Ingested Pb not absorbed passes in feces
• Enterohepatic circulation, biliary secretion
• Excretion by two pathways:– biliary excretion (major with high exposures)– urinary excretion (major)
![Page 23: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/23.jpg)
Susceptibility Factors
Genetic Predispositions• Inborn errors of haeme
metabolism (porphyrias)
• Hereditary anemias (e.g. the thalassemias)
Acquired Characteristics• Children < 6 y• Pregnant, lactating
women• Nutritional deficiency,
esp. Fe, Ca++, vit D• Neurological or renal
disease• ?Alcohol abuse
![Page 24: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/24.jpg)
Occupational Exposure Levels
OSHA PEL 0.05 mg/m3, 8-h TWA
NIOSH REL 0.10 mg/m3, 10-h TWA; BEI, Pb compounds covered differ
ACGIH TLV 0.05 mg/m3, 8-h TWA
![Page 25: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/25.jpg)
OSHA Pb Standard Actions
BPb >60 on asingle sample
Medicalremoval
Repeat BPb qmonth
BPb > 50 avelast 3 samples
Medicalremoval
Repeat BPb qmonth
BPb 40 - 60 Actionlevel is 50
Repeat BPb q 2months
BPb < 40 RTW:Confirm 2wks
Repeat BPb q 6months
![Page 26: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/26.jpg)
Management of Lead ExposureAdults
• Prohibit eating, drinking, smoking at work
• Housekeeping
• Ventilation
• Personal protection
• Medical removal
• Control exposure to OSHA Pb standard
• Review other possible sources of contamination
![Page 27: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/27.jpg)
Management of Lead ExposureChildren
• Optimize nutrition, avoid fasting• Report through public health dept. • Home Pb abatement
– Dust control– water– food containers– home and yard
• Rule out passive exposure
![Page 28: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/28.jpg)
Chelation
• Not a decision to be taken lightly
• Requires close monitoring
• Inefficient process, typically reducing body burden only 1 - 2 %
• Chelating agents may not significantly reduce tissue levels, esp. in CNS
![Page 29: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/29.jpg)
Chelation with Agents Other than Succimer
• Chelation can be dangerous!– May result in Ca++ depletion, hypercalcemia– May result in nephrotoxicity if serum Pb
• Agents– CaNa2EDTA 1000-1500 mg/m2/d, iv– BAL 300 - 450 mg/m2/d, 50 - 75 mg/m2 q4h
3 - 5 d, im– D - penicillamine (second-line drug)
![Page 30: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/30.jpg)
Chelation with Succimer
• Dimercaptosuccinic acid• Oral administration• Minimal side effects in decade of experience • Displaced D-penicillamine as oral agent since
1991• If adverse reactions to succimer, EDTA, D-
penicillamine is the alternative
![Page 31: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/31.jpg)
Paediatric Chelation Therapy - Encephalopathy - 1
• A medical emergency!
• BAL and CaNa2•EDTA at 1500 mg/m2/d, iv
• Stat BAL + continuous EDTA infusion
• EDTA alone may cause deterioration
• Generally continued 5 days
• D/C BAL at 3 days, continuing EDTA if prompt response and BPb <50 g/dl
![Page 32: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/32.jpg)
Paediatric Chelation Therapy - Encephalopathy - 2
• Fluid management critical– risk of cerebral edema, SIADH– monitor I/O, spec grav, electrolytes
• NPO for first several days• Adequate fluid replacements
– 1 ml/kcal/d energy requirements (100/kg first 10 kg, then 50 for next 10, thereafter 20)
– Urine output: 0.5 ml/kcal/d or 350 - 500 ml/m2/d
![Page 33: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/33.jpg)
Paediatric Chelation Therapy - Encephalopathy - 3
• Seizure control by benzodiazepines
• Suspect cerebral edema– avoid LP– mannitol, glycerol hyperosmotic therapy– modest hyperventilation– steroids– more aggressive management not evaluated
![Page 34: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/34.jpg)
Paediatric Chelation TherapyBPb > 70 g/dl
• If milder symptoms and/or blood Pb > 70 g/dl, chelation on regimen similar to encephalopathy
• 3 days of BAL + 5 days EDTA
• PICU for first few days
• Repeated courses only if required:– Second course should follow >2 d– Third course by 10 - 14 d, to equilibrate
![Page 35: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/35.jpg)
Paediatric Chelation TherapyBPb 45 - 69 g/dl
• If asymptomatic, treatment with succimer is preferred
• Succimer initiated with 30 mg/kg/d or 1050 mg/m2/d in three divided doses 5 d
• Succimer maintained at 20 mg/kg/d or 70 mg/m2/d in two divided doses 14 d
• Consider hospitalization if home abatement is not possible
![Page 36: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/36.jpg)
Paediatric Chelation TherapyBPb 20 - 44 g/dl
• CDC and AAP recommend environmental interventions but not chelation
• These guidelines considered conservative• Reasonable to consider chelation if:
– Pb levels do not decline – symptoms, even if subtle– elevated FEP after Fe supplementation– Age < 2 y
![Page 37: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/37.jpg)
Paediatric Chelation TherapyBPb 10 - 19 g/dl
• Excessive exposure to Pb
• Currently not considered as indication for chelation
• Home Pb abatement and control of exposure is recommended
![Page 38: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/38.jpg)
Indications for Paediatric Therapy May Change
• Safety of succimer may change recommendations
• NIEHS is sponsoring a clinical trial: Treatment of Lead-Exposed Children (TLC)– multicentre– randomized, double-blind– succimer v. placebo– outcomes include developmental indices
![Page 39: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/39.jpg)
Adult Chelation Therapy - 1
• Indicated for symptomatic Pb toxicity
• Generally less effective
• Never a substitute for control of exposure
• Unethical to give chelation for prophylaxis
• Indications for chelation depend on symptoms and BPb (g/dl), not BPb alone
![Page 40: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/40.jpg)
Adult Chelation Therapy - 2
Encephalopathy
Any BPb BAL +EDTA
Highdosages
Symptomatic
BPb > 100 BAL +EDTA
Lowerdosages
Mildsymptoms
BPb 70 -100
Succimerpo
Asymp-tomatic
BPb < 70 Medicalremoval
![Page 41: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/41.jpg)
Adult Chelation Therapy - 3
• Encephalopathy:– BAL 450 mg/m2/d, 75 mg im q4h 5 d– EDTA 1500 mg/m2/d, iv 5 d – Start EDTA 4 hours after stat BAL
• Symptomatic, BPb > 70– BAL 300 - 450 mg/m2/d, 50 - 75 mg im q4h
3 - 5 d– EDTA 1000 - 1500, otherwise as above
![Page 42: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/42.jpg)
Adult Chelation Therapy - 4
• Mild Symptoms treated with Succimer– Succimer 700 - 1050 mg/m2/d– Give 350 mg/m2 (or 10 mg/kg) 5 d, then bid
14 d
• The availability of a safe chelating agent does not mean that prophylaxis is acceptable.
![Page 43: Lead Sources of Occupational Exposure, Clinical Toxicology, and Control.](https://reader034.fdocuments.in/reader034/viewer/2022052307/551a9d39550346b52d8b63ec/html5/thumbnails/43.jpg)
Every Case of Lead Toxicity is a Failure of Society
• Lead toxicity is entirely preventable
• This problem should not exist in 2000
• A worker exposed to lead represents an insult in the present
• A child exposed to lead represents an assault on the future